Mirati Therapeutics
Mirati Therapeutics's Overview
Mirati Therapeutics, acquired by Bristol Myers Squibb (BMS) in January 2024 and now operating as a wholly owned subsidiary, is a biotechnology company that was focused on discovering and developing innovative, targeted oncology therapies. Mirati's research centered on addressing the genetic and immunological drivers of cancer, with a significant achievement being the development and FDA approval of KRAZATI® (adagrasib), a KRASG12C inhibitor for certain non-small cell lung cancer patients. The company's legacy mission was to transform the lives of patients with cancer by creating best-in-class medicines, a pursuit now continued within the BMS framework.
Where is Mirati Therapeutics's Headquarters?
HQ Function
Serves as a key research and development (R&D) and operational hub. Historically the corporate headquarters, it focuses on oncology drug discovery, clinical development, and strategic operations, now integrated within Bristol Myers Squibb's R&D structure.
Notable Features:
Modern laboratory facilities and office spaces designed to support advanced scientific research and collaboration in oncology drug development.
Work Culture:
Historically, Mirati fostered a science-driven, patient-focused, and agile work environment. The culture emphasized innovation, collaboration among teams, and a sense of urgency in addressing unmet medical needs in cancer. Post-acquisition, this specialized focus is integrating with Bristol Myers Squibb's broader corporate culture and values.
HQ Significance:
The San Diego site was pivotal for Mirati's key scientific breakthroughs, including the development of KRAZATI®. It remains a significant center for oncology research and development activities under BMS.
Values Reflected in HQ: The site reflects a commitment to cutting-edge scientific innovation, rigorous research, and a dedication to developing transformative cancer therapies, values that align with Bristol Myers Squibb's mission.
Location:
Prior to its acquisition, Mirati Therapeutics managed global clinical trials for its oncology drug candidates across North America, Europe, and Asia-Pacific. This involved functions such as clinical operations, regulatory affairs, and collaborations with international research institutions. As part of Bristol Myers Squibb, Mirati's programs and assets now leverage BMS's extensive global infrastructure for continued development, manufacturing, and commercialization efforts worldwide.
Street Address:
3545 Cray Court
City:
San Diego
State/Province:
CA
Country:
USA
Mirati Therapeutics's Global Presence
Cambridge, MA, USA
Address: One Broadway, Cambridge, MA 02142 (Note: This was likely a satellite office or shared workspace for regional operations prior to BMS acquisition)
To establish a strategic presence in the prominent New England biotechnology ecosystem, facilitating access to talent, research institutions, and partnership opportunities.
Buying Intent Signals for Mirati Therapeutics
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Mirati Therapeutics
As of April 2025, Mirati Therapeutics' leadership includes:
Investors of Mirati Therapeutics
Mirati Therapeutics has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
The most significant executive changes at Mirati Therapeutics over the past 12-24 months are directly linked to its acquisition by Bristol Myers Squibb, which was completed in January 2024. This corporate event led to the departure and transition of several key members of Mirati's senior leadership as the company's operations and teams began integrating into BMS. No new public executive appointments to a standalone Mirati entity have been announced post-acquisition; leadership for its assets and programs now resides within the Bristol Myers Squibb organizational structure.
Departures
Technology (Tech Stack) used by Mirati Therapeutics
Discover the tools Mirati Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Mirati Therapeutics Email Formats and Examples
Historically, Mirati Therapeutics likely utilized common corporate email formats such as first initial followed by the last name, or first name and last name separated by a period. For example, 'jdoe@mirati.com' or 'jane.doe@mirati.com'. Post-acquisition by Bristol Myers Squibb, communications would transition to BMS email systems for ongoing business.
flastname@mirati.com or first.lastname@mirati.com
Format
jdoe@mirati.com
Example
70%
Success rate
News and media
Bristol Myers Squibb News • January 23, 2024
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc. (NASDAQ: MRTX). With the completion of the acquisition, Mirati is now a wholly owned subsidiary of Bristol Myers Squibb. This strategic move enhances BMS's diverse oncology portfolio and strengthens its pipeline with promising assets like KRAZATI (adagrasib)....more
Bristol Myers Squibb News / Mirati Therapeutics Joint Release • October 8, 2023
Bristol Myers Squibb to Acquire Mirati Therapeutics for $58.00 Per Share in Cash, Advancing and Expanding Its Oncology Portfolio
Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb will acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion. The agreement also includes one non-tradeable contingent value right (CVR) per Mirati share, potentially worth $12.00 per share in cash....more
Mirati Therapeutics / PR Newswire • December 12, 2022
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI™ (adagrasib) as a targeted treatment for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. This approval marked a significant milestone for Mirati and patients with this specific mutation....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Mirati Therapeutics, are just a search away.